PURPOSE OF REVIEW: An increasing volume of research has been directed at the prevention of prostate cancer. This review proposes to summarize the large trials, novel approaches and molecular mechanisms of effect published in 2004 and 2005. RECENT FINDINGS: The impact of the Prostate Cancer Prevention Trial continues and subsequent articles have addressed the increase of high-grade prostate cancers detected in the finasteride arm of the trial, as well as the potential costs and benefits of extrapolating the findings to a public health campaign. Studies of risk have been published warning of excessive vitamin E and cyclooxygenase-2 inhibitor use in chemoprevention. Growing evidence supports the concept of chemopreventative agent combinations and further data on the roles of selenium, lycopene, soy, green tea, anti-inflammatories and statins in prostate-cancer prevention are presented. SUMMARY: Level one evidence exists for the preventative effects of finasteride in prostate cancer. The evidence for other agents is less conclusive but a number of large-scale, appropriately designed trials will hopefully address some of the relevant issues in prostate-cancer prevention over the next decade.
PURPOSE OF REVIEW: An increasing volume of research has been directed at the prevention of prostate cancer. This review proposes to summarize the large trials, novel approaches and molecular mechanisms of effect published in 2004 and 2005. RECENT FINDINGS: The impact of the Prostate Cancer Prevention Trial continues and subsequent articles have addressed the increase of high-grade prostate cancers detected in the finasteride arm of the trial, as well as the potential costs and benefits of extrapolating the findings to a public health campaign. Studies of risk have been published warning of excessive vitamin E and cyclooxygenase-2 inhibitor use in chemoprevention. Growing evidence supports the concept of chemopreventative agent combinations and further data on the roles of selenium, lycopene, soy, green tea, anti-inflammatories and statins in prostate-cancer prevention are presented. SUMMARY: Level one evidence exists for the preventative effects of finasteride in prostate cancer. The evidence for other agents is less conclusive but a number of large-scale, appropriately designed trials will hopefully address some of the relevant issues in prostate-cancer prevention over the next decade.
Authors: Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson Journal: Nat Rev Cancer Date: 2007-04 Impact factor: 60.716
Authors: Lucy E Hackshaw-McGeagh; Chris Penfold; Ellie Shingler; Luke A Robles; Claire M Perks; Jeff M P Holly; Edward Rowe; Anthony Koupparis; Amit Bahl; Raj Persad; Constance Shiridzinomwa; Lyndsey Johnson; Kalina M Biernacka; Aleksandra Frankow; Jayne V Woodside; Sarah Gilchrist; Jon Oxley; Paul Abrams; J Athene Lane; Richard M Martin Journal: BMJ Open Date: 2019-11-06 Impact factor: 2.692
Authors: Imtiaz A Siddiqui; Yogeshwer Shukla; Vaqar M Adhami; Sami Sarfaraz; Mohammad Asim; Bilal Bin Hafeez; Hasan Mukhtar Journal: Pharm Res Date: 2008-03-04 Impact factor: 4.200
Authors: Lucy Hackshaw-McGeagh; J Athene Lane; Raj Persad; David Gillatt; Jeff M P Holly; Anthony Koupparis; Edward Rowe; Lyndsey Johnston; Jenny Cloete; Constance Shiridzinomwa; Paul Abrams; Chris M Penfold; Amit Bahl; Jon Oxley; Claire M Perks; Richard Martin Journal: Trials Date: 2016-03-07 Impact factor: 2.279
Authors: S E T Larkin; H E Johnston; T R Jackson; D G Jamieson; T I Roumeliotis; C I Mockridge; A Michael; A Manousopoulou; E K Papachristou; M D Brown; N W Clarke; H Pandha; C L Aukim-Hastie; M S Cragg; S D Garbis; P A Townsend Journal: Br J Cancer Date: 2016-09-29 Impact factor: 7.640